Rethinking brain health
We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative diseases.
This gives us the potential to revolutionise how people think about brain health and disease management.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
Our products
Pharma/Biotech
- Measures you can trust
- Get more from your MRI
- Run targeted, more efficient clinical trials
- Efficient use of technology across multiple conditions
Clinical
- Better patient care
- Improving certainty in diagnosis
- Differential diagnosis for Dementia
- Accurately tracking decline
- Proactive brain health
Latest news
OBD Guest Speaker series Dr David Holtzman
A fascinating discussion with Dr Holtzman on the role APOE mutation plays in tau meditated neurodegeneration. Valubale insight into the P301S mutant tau transgenic mice (PS19) model and also acknowlegements that more work needs to be done on having better biomarkers of neuroimflammation as this fields gathers more focus and momentum. David Holtzman received his BS (1983) and MD (1985) from Northwestern University followed by a Neurology residency at UCSF from 1985-1989. He moved to Washington University in 1994 as an Assistant Professor and after moving up the faculty ranks and was Professor and Chair of Neurology at Washington University from 2003-2021. He is currently Professor of Neurology, scientific director of the Hope Center for Neurological Disorders, and Associate Director of the Knight ADRC. Several of his honors include being a recipient of the Potamkin prize and MetLife award for research on Alzheimer’s disease, Rainwater Prize for outstanding innovation in neurodegenerative disease research, election to the National Academy of Medicine, election to the National Academy of Inventors, being appointed to the National Advisory council of the NINDS and NIA, the Chancellor’s award for innovation and entrepreneurship and the Carl and Gerty Cori award from Washington University, elected Fellow of the AAAS, and being past president of the American Neurological Association.
OBD Guest Speaker series Dr Eric Siemers
It was a pleasure to welcome Dr Eric Siemers to our guest speaker series. He covered a range of topics from the history of AD clinical trials, trial design (using ACU193 as a case study) to sharing his viewpoint on the growing body of evidence that soluble Aβ oligomers are driving downstream pathology of AD. Eric Siemers, MD, has more than 25 years experience overseeing clinical trials of neurodegenerative disease and joined Acumen as Chief Medical Officer in 2018. He joined Eli Lilly and Company in 1998 and was responsible for several clinical trials for Alzheimer’s compounds, including five phase III studies as well as phase I and II studies. Prior to Lilly, Dr. Siemers founded the Indiana University Movement Disorder Clinic, where his research included Parkinson’s and Huntington’s disease. Dr. Siemers served on the NIA/Alzheimer’s Association working group that proposed new research nomenclature for Alzheimer’s disease utilizing biomarkers and clinical symptoms. He was a founding member of the Alzheimer’s Association Research Roundtable and was on the steering committee for the Alzheimer’s Disease Neuroimaging Initiative. Dr. Siemers earned his MD from the Indiana University School of Medicine.
OBD selected to talk at AD/PD 2023 Conference.
Oxford Brain Diagnostics are pleased to announce we have once again been selected to speak at the forthcoming ADPD2023 conference in Gothenberg, Sweden. Special thanks goes to Banner Health as our collaborators in this abstract. We invite all our colleagues, friends and partners to listen into our talk. It will take place at SYMPOSIUM: FLUID BIOMARKERS AND IMAGING IN AD, PD AND PSP. Our session starts at 16:15 (CET), HALL G3, 01 Apr. - 'CORTICAL DIFFUSIVITY SHOWS GREATER SENSITIVITY THAN CORTICAL THICKNESS TO EARLY NEURODEGENERATIVE CHANGES AROUND THE TRANSITION TO MILD COGNITIVE IMPAIRMENT'.
OBD Guest Speaker series Dr Henrik Zetterberg
Dr Zetterberg provides a comprehensive update on the role of blood-based biomarkers (BBB) in Alzheimer’s pathology. He provides an incredibly balanced and realistic perspective on the various biomarkers currently being investigated for both drug development and clinical utility. It was clear during the discussions that while BBB’s provide an easier and more convenient route to detecting Amyloid and Tau presence, additional biomarkers and diagnostics tools will need to be incorporated to achieving a more accurate diagnosis for patients. Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at the Sahlgrenska University Hospital in Gothenburg. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, and his main research focus and clinical interest is fluid biomarkers for central nervous system diseases. He has published more than 900 papers and has received numerous awards.
